v3.25.1
GENERAL ORGANIZATION, BUSINESS AND LIQUIDITY (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2025
USD ($)
item
Mar. 31, 2024
USD ($)
Dec. 31, 2024
USD ($)
Cash, cash equivalents, short-term investments, and restricted cash $ 366,100    
Cash and cash equivalents 171,668 $ 134,188 $ 115,694
Short-term investments 188,045   208,087
Restricted cash 6,381 6,430 $ 6,400
Net Loss 116,163 112,976  
Net cash used in operating activities $ 103,694 $ 122,279  
Minimum | Amtagvi      
Number of patients to be treated annually | item 20,000